ESR1 and neoplasm: In 2010, the guidelines of the American Society of Clinical Oncology and the College of American Pathologists (ASCO/CAP) defined ER-positive tumors as those with ≥ 1% of tumor cell nuclei exhibiting immunoreactivity because of the substantial impact of endocrine therapies on mortality reduction in these patients [11].